Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02633098
Other study ID # 15.0154
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 26, 2017
Est. completion date October 31, 2025

Study information

Verified date October 2021
Source St George's, University of London
Contact Professor Sanjeev Krishna, FRCP, ScD, FMedSci
Phone ++44(0)208 725 5836
Email s.krishna@sgul.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells. Two hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200mg daily or a matching placebo for 14 days prior to surgery. Patients will be followed up closely for 5 years to see if giving artesunate preoperatively reduces the risk of cancer recurring after surgery.


Description:

Artesunate is an established antimalarial drug belonging to the artemisinin class of drugs, has an excellent safety profile, is well tolerated and affordable. In last two decades, artemisinins have shown potent and broad anticancer properties in a range of cell lines and animal models, supporting the hypothesis that artemisinins have the potential to be an effective anti-cancer therapy. Multiple potential mechanisms of action include anti-proliferative effects through cell-cycle disruption, reactive oxygen species (ROS) -induced DNA damage, induction of apoptosis, anti-angiogenesis, immunomodulation and induced radiosensitivity. Despite a multi-modality treatment approach to colorectal cancer, 5 year overall survival does not currently exceed 60%. Neoadjuvant pre-operative therapy may be more effective at eradicating micrometastases compared to adjuvant therapy delivered following the delay and immunological stress of surgery. However current neoadjuvant chemotherapy regimens are often associated with significant side effects and may result in a delay in surgery whilst patients recover. A well tolerated, affordable, novel anticancer agent that could be given to patients whilst they wait for surgery, without causing a surgical delay due to treatment related toxicity, would have a significant clinical impact on patient care. The NeoART trial is a phase II multicentre randomised, double blind, placebo controlled trial (RCT) for patients undergoing primary surgery for Stage II/III colorectal cancers. Patients are randomised (1:1 ratio) to receive either a two week course of neoadjuvant artesunate 200mg once daily or matching placebo. Both patients and health care professionals are blinded to treatment allocation arm to minimise outcome-reporting bias. The primary endpoint of the trial is recurrence free survival two years after surgery. Secondary endpoints include 2 and 5 year overall survival, treatment related toxicity, tolerability and patient quality of life. A translational sub-study looking at predictive and prognostic biomarkers is also planned.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 31, 2025
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria 1. Aged 18 or over 2. Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer 3. Stage II/III colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy/chemoradiation therapy 4. WHO performance status 0,1 or 2 5. Adequate full blood count: White Cell Count (WCC) >3.0 x 10^9 /l; Platelets >100 x 10^9/l; Haemoglobin (Hb) >80g/L 6. Adequate renal function: Glomerular Filtration Rate >30ml/min by Cockcroft-Gault formula 7. Adequate hepatobiliary function : Bilirubin < 3 x Upper limit normal 8. Female participants of child bearing potential must have a negative pregnancy test < 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention 9. Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention 10. Patient able and willing to provide written, informed consent for the study. Exclusion criteria 1. Contraindication to the use of artesunate due to hypersensitivity 2. Pregnancy or lactation 3. Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film); or agreement of true abstinence from time to consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation methods are not considered acceptable methods) 4. History of immunosuppression 5. History of hearing or balance problems 6. Weight < 52kg or > 110kg 7. Other planned intervention, apart from standard of care 8. Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ 9. Lactose intolerance

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Artesunate 200mg
Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
Placebo
Matched placebo PO OD for 14 days prior to colorectal resection surgery

Locations

Country Name City State
United Kingdom Barking, Havering and Redbridge University Hospitals NHS Trust Barking
United Kingdom Ashford & St Peters Hospital NHS Foundation Trust Chertsey
United Kingdom University Hospitals of Derby and Burton NHS Foundation Trust Derby
United Kingdom Medway Maritime Hospital Gillingham Kent
United Kingdom St George's University Hospitals NHS Fundation Trust London
United Kingdom Kent Oncology Centre, Maidstone Hospital Maidstone Kent
United Kingdom Norfolk & Norwich University Hospitlas NHS FT Norwich
United Kingdom Shrewsbury and Telford Hospital NHS Trust Shrewsbury

Sponsors (1)

Lead Sponsor Collaborator
St George's, University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence free survival at 2 years 2 years following study randomisation.
Secondary Recurrence free survival at 5 years 5 years from study randomisation
Secondary Overall survival at 2 and 5 years 2 and 5 years from study randomisation
Secondary Colon cancer specific death at 2 and 5 years 2 and 5 years from study randomisation
Secondary Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 7 following start of study intervention (artesunate/matching placebo)
Secondary Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 14 following start of study intervention (artesunate/matching placebo)
Secondary Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 42 following start of study intervention (artesunate/matching placebo)
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 7 following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 14 following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 42 following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 6 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 12 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 18 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 24 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 30 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 36 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 42 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 48 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 54 months following study intervention
Secondary Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 60 months following study intervention
Secondary Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin) Post surgical pathology review (following Day 14 of study intervention)
Secondary Patient quality of life Using validated quality of life self-administered questionnaires Assessment at Day 1 of study intervention
Secondary Patient quality of life Using validated quality of life self-administered questionnaires Assessment at Day 7 of study intervention
Secondary Patient quality of life Using validated quality of life self-administered questionnaires Assessment at Day 14 of study intervention
Secondary Patient quality of life Using validated quality of life self-administered questionnaires Assessment at Day 42 of study intervention
Secondary Surgical complications Number of patients with surgery related adverse events as assessed by CTCAE v4.0 From time of surgery up to 3 months post surgery
Secondary Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy Assessment at Day 1 of study intervention
Secondary Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy Assessment at Day 7 of study intervention
Secondary Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy Assessment at Day 14 of study intervention
Secondary Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy Assessment at Day 42 of study intervention
Secondary Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status Number of patients with Kras mutant tumours Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status Number of patients with Mismatch Repair (MMR) mutant tumours Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status Number of patients with BRAF mutant tumours Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression Number of patients whose tumours show PDGFR upregulation/downregulation following study intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression Number of patients whose tumours show VEGF upregulation/downregulation following study intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining) Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway Number of patients whose tumour samples show activation of the DDR pathway following study intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Secondary Wnt/ß-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins) Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/ß-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention Pre and post intervention tumour samples from patients (Day 0 and Day 15)
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A